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Invasive candidiasis is the most common fungal disease among hos-pitalized patients in the developed world. Invasive candidiasis comprises both candidemia and deep-seated tissue candidiasis. Candidemia is generally viewed 
as the more common type of the disease, and it accounts for the majority of cases 
included in clinical trials. Deep-seated candidiasis arises from either hematoge-
nous dissemination or direct inoculation of candida species to a sterile site, such 
as the peritoneal cavity (Fig. 1). Mortality among patients with invasive candidiasis 
is as high as 40%, even when patients receive antifungal therapy. In addition, the 
global shift in favor of nonalbicans candida species is troubling, as is the emerging 
resistance to antifungal drugs. During the past few years, new insights have sub-
stantially changed diagnostic and therapeutic strategies.
Epidemiol o gy
According to conservative estimates, invasive candidiasis affects more than 
250,000 people worldwide every year and is the cause of more than 50,000 deaths. 
Incidence rates of candidemia have been reported to be between 2 and 14 cases 
per 100,000 persons in population-based studies.1,2 Candidemia has often been 
cited as the fourth most common bloodstream infection.3 Although this statistic 
applies to intensive care units (ICUs), in most population-based studies candi-
demia is reported as the seventh to tenth most common bloodstream infection. 
Incidence rates have been increasing or stable in most regions, although declining 
rates have been reported in high-incidence areas after improvements in hygiene 
and disease management were introduced.2,4,5
The incidence of candidemia is age-specific, with the maximum rates observed 
at the extremes of age. Risk factors are summarized in Table 1.2,6,7 The presence 
of central vascular catheters, recent surgery (particularly abdominal surgery with 
anastomotic leakages), and the administration of broad-spectrum antibiotic ther-
apy constitute the major risk factors for invasive candidiasis. Although candidemia 
has been described as the most common manifestation of invasive candidiasis, 
blood-culture–negative forms include syndromes such as chronic disseminated 
(hepatosplenic) candidiasis in patients with hematologic cancers and deep-seated 
infection of other organs or sites, such as the bones, muscles, joints, eyes, or cen-
tral nervous system. Infections at most of these sites arise from an earlier or un-
diagnosed bloodstream infection. Conversely, the direct introduction of candida 
may occur at a sterile site, resulting, for example, in ascending renal candidiasis 
or candida peritonitis after intestinal surgery.8 Deep-seated infections may remain 
localized or lead to secondary candidemia. The limited published data available 
suggest that invasive abdominal candidiasis may be much more common than 
recognized.8,9
From the Department of Medicine and 
Radboudumc Center for Infectious Dis-
eases, Radboud University Medical Cen-
ter, Nijmegen, the Netherlands (B.J.K.); 
and the Department of Microbiology and 
Infection Control, Statens Serum Institut, 
Copenhagen (M.C.A.). Address correspon-
dence to Dr. Kullberg at the Department 
of Medicine, Radboud University Medical 
Center, P.O. Box 9101, 6500 HB Nijmegen, 
the Netherlands, or at  bj . kullberg@ 
 radboudumc . nl.
N Engl J Med 2015;373:1445-56.
DOI: 10.1056/NEJMra1315399
Copyright © 2015 Massachusetts Medical Society.
Edward W. Campion, M.D., Editor
Invasive Candidiasis
Bart Jan Kullberg, M.D., Ph.D., and Maiken C. Arendrup, M.D., Ph.D. 
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;15 nejm.org October 8, 20151446
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
 C a ndida Species
The species distribution has changed over the past 
decades. Whereas Candida albicans had previously 
been the dominating pathogen, this species today 
accounts for only half the isolates detected in 
many surveys.1,2,10 C. glabrata has emerged as an 
important pathogen in northern Europe, the Unit-
ed States, and Canada, whereas C. parapsilosis is 
more prominent in southern Europe, Asia, and 
South America. Changes in species distribution 
may drive treatment recommendations, given the 
Figure 1. Pathogenesis of Invasive Candidiasis.
Candida species that colonize the gut invade through translocation or through anastomotic leakage after laparoto-
my and cause either localized, deep-seated infection (e.g., peritonitis), or candidemia. In patients with indwelling in-
travascular catheters, candidemia that originates from the gut or the skin leads to colonization of the catheter and 
the formation of biofilm. Fungi are subsequently released from the biofilm, causing persistent candidemia. Once 
candidemia has developed, whether from a colonized intravascular catheter or by other means, the fungi may dis-
seminate, leading to secondary, metastatic infections in the lung, liver, spleen, kidneys, bone, or eye. These deep-
seated infections may remain localized or lead to secondary candidemia. During candidemia, the fungi in the blood-
stream may enter the urine, leading to candiduria. Less frequently, deep-seated candidiasis may occur as a result of 
ascending pyelonephritis and may either remain localized or lead to secondary candidemia.
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differences in susceptibility to azoles and echino-
candins among these species.
Candida species differ considerably in viru-
lence. C. parapsilosis and C. krusei are less virulent 
than C. albicans, C. tropicalis, and C. glabrata.11 This 
variation is reflected in the low mortality among 
patients with C. parapsilosis candidemia and in 
the fact that infection with C. krusei is highly un-
common except in patients with severe immuno-
deficiency and prior exposure to an azole.6 Despite 
its low virulence, C. parapsilosis can thrive in cer-
tain clinical settings owing to its ability to adhere 
to medical devices and its propensity to colonize 
human skin, characteristics that facilitate noso-
comial outbreaks.12 Other species that appear with 
less frequency in clinical settings, such as C. dubli-
niensis, C. lusitaniae, C. kefyr, and C. guilliermondii, are 
associated with specific susceptibility patterns or 
with specific hosts (e.g., C. dubliniensis has been 
particularly common in HIV-infected patients).
Immuno gene tics of C a ndida 
Infec tions
The majority of patients in the ICU do not acquire 
invasive candidiasis, even if they share similar 
risk factors. Thus, it is likely that variation in the 
genes that confer susceptibility to candida infec-
tion makes certain patients more prone to infec-
tion. A large clinical study revealed that suscep-
tibility to candidemia was increased among 
European and North American patients who had 
single-nucleotide polymorphisms (SNPs) in the 
toll-like receptor 1–interferon-γ pathway, as com-
pared with a clinical control cohort matched for 
underlying disease.13 In a genomewide association 
study in which susceptibility to candidemia was 
assessed, three new genes associated with an in-
creased risk of disease were identified. Patients 
in the ICU who carried two or more alleles at 
these particular loci had a risk of candidemia that 
was 19 times as high as the risk among patients 
who did not have those alleles.14 Similarly, disease 
progression and persistent candidemia despite 
antifungal therapy were associated with cyto-
kine polymorphisms that led to either increased 
circulating levels of antiinflammatory interleu-
kin-10 or decreased levels of proinflammatory 
interleukin-12b cytokine.15 These findings under-
score the importance of cytokine balance with 
respect to both the susceptibility to acquiring in-
vasive candidiasis and the ability to clear the in-
fection once it has been disseminated. The iden-
tification of specific alleles related to the risk of 
disease and of cytokine pathways associated with 
unfavorable outcomes suggests that screening 
strategies based on the presence or absence of 
certain SNPs may help to identify patients at risk 
who could benefit from prophylactic antifungal 
treatment or adjunctive immunotherapy.16
Di agnosis
The armamentarium available for diagnosing 
invasive candidiasis includes direct detection, in 
which specimens of blood or tissue from normally 
Critical illness, with particular risk among patients with long-term ICU stay
Abdominal surgery, with particular risk among patients who have anastomotic leakage or have had repeat laparotomies
Acute necrotizing pancreatitis
Hematologic malignant disease
Solid-organ transplantation
Solid-organ tumors
Neonates, particularly those with low birth weight, and preterm infants
Use of broad-spectrum antibiotics
Presence of central vascular catheter, total parenteral nutrition
Hemodialysis
Glucocorticoid use or chemotherapy for cancer
Candida colonization, particularly if multifocal (colonization index >0.5 or corrected colonization index >0.4)
*  ICU denotes intensive care unit. For further information see Cleveland et al.,2 Arendrup et al.,6 and Lortholary et al.7
Table 1. Risk Factors for Invasive Candidiasis.*
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sterile sites are cultured, and indirect detection, 
in which surrogate markers and polymerase-chain-
reaction (PCR) assays are used (Table 2).18,21,22 No 
test is perfect, and it is therefore necessary to 
perform several diagnostic tests to achieve max-
imal accuracy.
Culture is currently the only diagnostic ap-
proach that allows subsequent susceptibility test-
ing. The sensitivity of blood cultures is far from 
ideal, with a sensitivity of 21 to 71% reported in 
autopsy studies.9 Whereas blood cultures may 
establish a diagnosis during the period when can-
dida resides in the bloodstream, cultures of blood 
obtained from patients with hematogenous, deep-
seated infections often yield negative results be-
cause candida has been cleared from the blood-
stream at the time the blood sample is collected.9 
Blood cultures are further limited by slow turn-
around times and by the fact that a positive re-
sult may be revealed only late in the course of 
disease. Positive blood cultures should prompt 
the immediate initiation of therapy and a search 
for metastatic foci.18,31
Candida mannan antigens and antimannan 
antibodies and β-d-glucan are the primary sur-
rogate markers for invasive candidiasis.18,21,22 The 
reported performance of assays for these mark-
ers varies somewhat according to case mix, the 
frequency of sampling, and the choice of com-
parator. Studies that include healthy controls or 
less severely ill patients may overestimate speci-
ficity, since there are many potential sources of 
contamination of β-d-glucan testing that can 
produce false positive results, and these are 
found more frequently in patients at high risk 
for invasive candidiasis (Table 2). The major di-
agnostic benefit of β-d-glucan is its negative 
predictive value for invasive candidiasis in envi-
ronments in which the prevalence is low to 
moderate.
A number of in-house PCR tests for the detec-
tion of invasive candidiasis have been evaluated. 
However, limited validation and standardization 
have hindered their acceptance and implementa-
tion.27 Nguyen et al. reported that an in-house 
PCR assay had a sensitivity of 89% for deep-seated 
candidiasis that was not detected on blood cul-
tures.28 Two commercial PCR tests have been mar-
keted — the SeptiFast and the fully automated 
multiplex T2Candida Panel, which was released 
in 2015.29,30 The T2Candida Panel has recently 
been tested in one clinical trial that produced 
promising results (Table 2).30
Proph y l a x is
In view of the high mortality associated with in-
vasive candidiasis, prophylaxis for selected patients 
in the ICU who are at high risk for the disease 
would appear to be appropriate. Until now, the 
use of antifungal prophylaxis in patients in the 
ICU has received little support from clinical 
studies, except for its use in specific high-risk 
groups.32 In patients who have had recent ab-
dominal surgery and have recurrent gastrointesti-
nal perforations or anastomotic leakage, flucon-
azole prophylaxis has been shown to be effective.33 
In other selected patient groups in the ICU, the 
results have been modest at best. Antifungal 
prophylaxis has generally shown trends toward 
reducing the incidence of candidemia by approxi-
mately 50%, but this strategy has not been shown 
to improve survival.34,35 The major challenge is to 
select individual patients or subgroups that will 
benefit most from prophylaxis in order to limit 
the number needed to treat and to avoid the 
problem of selective pressure that leads to the 
emergence of resistance.
A recent randomized, placebo-controlled study 
used targeted caspofungin prophylaxis in patients 
in the ICU who were determined to be at high 
risk for invasive candidiasis with the use of a 
clinical prediction rule.36 In this study, both se-
rum β-d-glucan levels and cultures were used to 
define invasive candidiasis. Overall, there were 
no significant differences between the study 
groups in the incidence of candidemia, all-cause 
mortality, the use of antifungal drugs, or the 
length of stay. In these types of placebo-con-
trolled studies, culture- and biomarker-based end 
points may be less appropriate, since they are 
likely to be biased in favor of the group receiving 
the study drug. At this time, antifungal prophy-
laxis should be limited to patients in whom it 
has proved to be beneficial: patients with gastro-
intestinal anastomotic leakage, patients under-
going transplantation of the pancreas or the 
small bowel, selected patients undergoing liver 
transplantation who are at high risk for candi-
diasis, and extremely low-birth-weight neonates 
in settings with a high incidence of neonatal 
candidiasis.
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E a r ly Tr e atmen t
Retrospective observational studies have sug-
gested that early presumptive antifungal therapy 
(therapy based on symptoms or biomarkers) is 
associated with reduced mortality among patients 
with invasive candidiasis.37 Support has been pro-
vided by recent multivariate analyses, which cor-
rected for confounders that were likely to intro-
duce bias in observational cohort studies. These 
analyses consistently identified the early use of 
appropriate antifungal therapy and control of the 
source of infection as major determinants of sur-
vival.38-40 Thus, although it is plausible that early, 
presumptive treatment of patients with invasive 
candidiasis is beneficial, such strategies have not 
been validated by prospective studies.
More refined approaches include treatment 
that is driven by prediction rules based on clini-
cal risk factors, the presence of candida coloni-
zation, and the results of screening for serum 
β-d-glucan,25,41 but to date no such approach has 
been shown to reduce mortality or length of stay 
in prospective studies. In addition, published pre-
diction rules are not generally applicable in re-
gions or settings that are different from those in 
the study.42,43
The clinical usefulness of prediction rules is 
affected by the low prevalence of invasive candi-
diasis.9,43 In typical ICU settings, where the pre-
test likelihood of candidiasis is 0.5 to 10%, both 
individual, non–culture-based tests and risk-
factor–based rules, which have a specificity of 
50 to 80%, will lead to a positive predictive value 
of merely 1 to 30%.42 Rather than being seen as 
definitive diagnostic tools, prediction rules and 
nonculture-based tests might be best viewed as 
markers that aid in the assessment of the pos-
sibility that a patient has invasive candidiasis.9
Choice of A n tifung a l Ther a py
Three classes of antifungal drugs are available 
for the treatment of invasive candidiasis (Table 3), 
and each new antifungal drug has been com-
pared with a preexisting standard regimen in 
randomized trials. However, these studies were 
powered for noninferiority, and prospective 
studies intended to assess the superiority of one 
antifungal class of drug over another and to 
identify the most effective antifungal treatment 
strategies are unavailable.
Early studies showed that fluconazole, vori-
conazole, and caspofungin were as effective as 
amphotericin B deoxycholate and were associat-
ed with significantly lower levels of toxic effects 
and of treatment discontinuation.44,45,47 The re-
sults of such studies marked the end of the use 
of amphotericin B deoxycholate as a treatment 
option for invasive candidiasis, except in envi-
ronments with limited resources.31 Micafungin 
was shown to be as effective as caspofungin and 
liposomal amphotericin B in two subsequent com-
parative trials.49,50
A pivotal study compared the efficacy of an-
idulafungin with that of fluconazole.48 Although 
the study had been designed to assess the non-
inferiority of anidulafungin, overall response rates 
were significantly higher with anidulafungin than 
with fluconazole (76% vs. 60%; P = 0.01). The ap-
parent superiority of anidulafungin over flucon-
azole was most distinct in patients infected with 
C. albicans (global response, 81% vs. 62%; P = 0.02), 
even though the C. albicans was almost uniformly 
susceptible to fluconazole.48 Inferior outcomes 
with fluconazole were also observed in patients 
with low scores (indicating less severe disease) 
on the Acute Physiology and Chronic Health Evalu-
ation (APACHE II), which suggested that inferior 
outcomes with fluconazole were not related to 
severity of illness. Post hoc multivariate analyses 
have not indicated that the differences in outcome 
with each drug were related to other, confounding 
factors.51 Nevertheless, the question of whether 
a single noninferiority trial can establish the 
superiority of echinocandins over azoles for the 
treatment of invasive candidiasis has remained 
controversial, and opinions among experts in 
mycology are divided.
More recent studies have provided reasonable 
support, but no formal proof, for the superiority 
of echinocandins as treatment for the majority 
of patients with invasive candidiasis. Most no-
table is the pooled analysis of patient-level data 
from seven randomized trials that assessed anti-
fungal treatments.38 With 30-day all-cause mor-
tality used as an unequivocal end point, the most 
important finding was that randomization to an 
echinocandin was associated with better survival 
rates and greater clinical success than treatment 
with a triazole or amphotericin B. The improved 
outcomes were most evident among patients in-
fected with C. albicans or C. glabrata. The benefit of 
echinocandin therapy was observed among pa-
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tients with APACHE II scores in all but the 
highest quartiles, suggesting that the survival 
benefit associated with echinocandin treatment 
is not limited to the sickest patients.38 In addi-
tion to treatment with an echinocandin antifun-
gal agent, the removal of intravenous catheters 
was an independent determinant of improved 
survival.38
Several cohort studies in which multivariate 
models were used have consistently identified 
treatment with an echinocandin and catheter 
removal as the management strategies associat-
ed with better outcomes.40,52 Additional data 
have provided reasonable support for the effica-
cy of echinocandins in patients in the ICU, pa-
tients with deep-seated candidiasis, and patients 
infected with species other than C. albicans.53,54 
The observation that success rates among pa-
tients infected with C. parapsilosis are as good as 
those among patients infected with other species 
should be regarded with some caution. C. parapsi-
losis is less susceptible to the echinocandins than 
other candida species at the cellular and enzyme 
level and tends to be associated with higher per-
sistence and breakthrough rates among patients 
receiving an echinocandin.45
Clinical trials and hence treatment guidelines 
are biased toward patients with candidemia, 
since the infection is easier to recognize and the 
patients easier to enroll in clinical studies than 
patients with deep-seated candidiasis. In addi-
tion, the comparison of trials is hampered, since 
the studies have been conducted over an extended 
period during which many advances in care have 
been introduced. Despite these caveats, echino-
candins are suggested to be associated with bet-
ter outcomes than those with azoles regardless of 
the type of invasive candidiasis, APACHE II score, 
and candida species (except for C. parapsilosis), and 
it is hard to justify withholding these agents as 
the first choice for treatment.55 Nevertheless, 
some experts believe that there is a subgroup of 
ambulatory, stable, low-risk patients for whom 
primary therapy with fluconazole is acceptable. 
Moreover, there are clinical scenarios in which 
triazoles may be preferred, such as in the treat-
ment of meningitis, endophthalmitis, and uri-
nary tract candidiasis (conditions in which echi-
nocandins are limited by their pharmacokinetics) 
or in the treatment of patients who have previ-
ously been exposed to echinocandins for pro-
longed periods.
Dur ation of Ther a py a nd  
S tep -D ow n C a r e
Few data are available to support recommenda-
tions regarding the total duration of therapy or 
the step-down procedure from echinocandins to 
intravenous or oral azoles.56 Since it is assumed 
that initial therapy with echinocandins is most 
effective in preventing death, the primary re-
quirement for the transition to azoles should be 
the clinical stabilization of the patient rather 
than identification of the infecting species and 
its susceptibility to azoles only — with the prob-
able exception of C. parapsilosis infection.
Recent phase 4 studies have incorporated a 
step-down strategy to an oral azole as early as 
5 days after the start of intravenous treatment 
with an echinocandin, provided that the infect-
ing candida species has been cleared from the 
bloodstream and is probably susceptible to 
azoles and that the patient’s condition is clini-
cally stable and the patient is capable of taking 
oral therapy.54 The outcomes of a strategy of early 
step-down with respect to efficacy and survival 
were similar to those reported in previous studies 
in which a minimum of 10 days of parenteral 
echinocandin therapy were required.54 However, 
the intent of these studies was not to compare 
the effects of early step-down therapy with pro-
longed echinocandin therapy in a randomized 
fashion, and the patients who underwent the 
transition to azoles were less severely ill than 
other patients.
C athe ter M a nagemen t
The concept supporting removal of intravascular 
catheters in patients with candidemia is based 
on the identification of catheters as a major risk 
factor for candidemia, the presence of biofilms 
of candida species attached to catheters, and the 
observation that candidemia may persist until 
catheters have been removed. However, no blind-
ed, randomized studies have been designed to 
determine the effect of catheter removal on out-
comes and mortality. It is unlikely that such a 
study will ever be performed, and retrospective 
subgroup analyses have shown divergent out-
comes.38,57,58 Although a careful analysis could 
not identify a significant effect of early catheter 
removal within 24 or 48 hours after initiation of 
treatment,57 other studies found that catheter 
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removal at any time point was associated with a 
reduction in mortality and higher clinical suc-
cess rates.39,40,58 In the pooled patient-level analy-
sis of seven randomized treatment trials, treat-
ment with an echinocandin and catheter removal 
were identified as the two modifiable manage-
ment strategies associated with better survival.38 
Because patients have to be alive to have a cath-
eter removed, these types of analyses may not be 
free of bias. Although the debate about this issue 
will continue, it seems wise to remove all intra-
vascular catheters in patients with candidemia, 
if logistically feasible.31,55,59
Emerging R esis ta nce
Resistance to antifungal treatment can emerge 
either by means of the selection of species with 
intrinsic resistance or an induction of resistance 
in isolates from species that are normally sus-
ceptible. The former route is the most common, 
as illustrated by the emergence of C. glabrata after 
the introduction of fluconazole and of C. parapsilo-
sis in settings in which there was increased use 
of echinocandins (Fig. 2).6,60 In addition, insuf-
ficient dosing of azoles has been associated with 
the emergence of resistance.61
Figure 2. Distribution of Candida Species According to Duration of Prophylaxis and Antifungal Agent Used for Prophylaxis.
Panel A shows the distribution of candida species isolated from the bloodstream of patients with candidemia in a Danish study.6 From 
left to right, the graphs show the distribution in patients who had received no antifungal prophylaxis at the time of blood culture (258 
patients), those who had received antifungal prophylaxis for less than 7 days at the time of culture (21 patients), and those who had re-
ceived antifungal prophylaxis for at least 7 days at the time of culture (28 patients) (P = 0.007 according to the chi-square test). Antifun-
gal prophylaxis included fluconazole in 37 patients (70%), voriconazole in 2 patients (4%), caspofungin in 6 patients (11%), and an am-
photericin B formulation in 8 patients (15%) (some patients received more than one drug). Panel B shows the distribution of candida 
species isolated from the bloodstream of patients with candidemia in a French study.60 From left to right, the graphs show the distribu-
tion in patients who had received no antifungal prophylaxis at the time of blood culture (2289 patients with no fluconazole exposure, 
and 2387 patients with no echinocandin exposure), those who had received fluconazole before the blood culture was performed (159 
patients), and those who had received caspofungin before the blood culture was performed (61 patients).
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Candida isolates with acquired resistance to 
echinocandins have been reported with increas-
ing frequency.62 C. glabrata is overrepresented 
among echinocandin-resistant isolates, with re-
sistance rates of 2 to 5% and up to 8 to 12% at 
selected centers for tertiary care.62,63 Acquired re-
sistance to echinocandins has also been reported 
for C. albicans, C. tropicalis, C. krusei, C. kefyr, C. lu-
sitaniae, and C. dubliniensis.62 Recent studies indi-
cate that the rate of acquired resistance to echi-
nocandins in isolates from sources other than 
blood may be underestimated, which suggests 
that deep-seated candidiasis may act as a hidden 
reservoir of echinocandin resistance.64
Conclusions a nd Fu t ur e 
Per spec ti v es
The management of invasive candidiasis has 
changed markedly during the past decade. Chang-
es in epidemiology and the emergence of resis-
tance, against both triazoles and echinocandins, 
merit vigilance. We have entered a new era in 
which better outcomes for patients with invasive 
candidiasis are less likely to result from new 
drugs than from early intervention strategies that 
are based on a combination of clinical prediction 
rules, non–culture-based tests (e.g., PCR assays or 
tests for antigens), and, ultimately, personalized, 
immunogenetics-based risk profiles. At present, 
the most important need is for studies that will 
validate the role of nonculture-based diagnostics 
in presumptive early treatment strategies.
Accumulating evidence points to the impor-
tance of early and appropriate antifungal treat-
ment as a major driver of outcomes. Echinocan-
dins appear to be the drugs of first choice for 
most patients, irrespective of the severity of ill-
ness. This development has marked a paradigm 
shift in the treatment of invasive candidiasis: 
treat early with an echinocandin and step down 
early to a triazole, giving consideration to the 
clinical stabilization of the patient, the candida 
species, and its susceptibility. By defining the most 
effective approach to the management of invasive 
candidiasis, we may finally begin to see declining 
mortality among patients with candidemia.
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